Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
American Journal of Obstetrics and Gynecology
|
October 18, 2017
Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study
Erin A Bishop, James J Java, Kathleen N Moore, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
Gynecologic Oncology
|
July 12, 2025
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)
Sarah S Lee, Angeles Alvarez Secord, Steven Friedman, et al.
Gynecologic Oncology
|
May 24, 2017
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study
Henry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
January 4, 2021
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients
Heather Hampel, Rachel Pearlman, Albert de la Chapelle, et al.
Gynecologic Oncology
|
July 19, 2022
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
Dana M Chase, Margarita Romeo Marín, Floor Backes, et al.
Gynecologic Oncology
|
September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Jubilee Brown, Austin Miller, Laura L Holman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial
Ann H Klopp, Danielle Enserro, Matthew Powell, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
American Journal of Obstetrics and Gynecology
|
October 18, 2017
Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study
Erin A Bishop, James J Java, Kathleen N Moore, et al.
Gynecologic Oncology
|
April 11, 2024
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Lilian T Gien, Danielle M Enserro, Matthew S Block, et al.
Gynecologic Oncology
|
July 12, 2025
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)
Sarah S Lee, Angeles Alvarez Secord, Steven Friedman, et al.
Gynecologic Oncology
|
May 24, 2017
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study
Henry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
January 4, 2021
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients
Heather Hampel, Rachel Pearlman, Albert de la Chapelle, et al.
Gynecologic Oncology
|
July 19, 2022
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
Dana M Chase, Margarita Romeo Marín, Floor Backes, et al.
Gynecologic Oncology
|
September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Jubilee Brown, Austin Miller, Laura L Holman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial
Ann H Klopp, Danielle Enserro, Matthew Powell, et al.
Page
of 6